Paradigm Biopharmaceuticals Limited (PBIGF)
USD 0.38
(0.0%)
USD 0.38
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 27.39 Million AUD | -59.16% |
| 2023 | 67.06 Million AUD | 32.32% |
| 2022 | 50.68 Million AUD | -40.22% |
| 2021 | 84.79 Million AUD | -24.54% |
| 2020 | 112.36 Million AUD | 31.4% |
| 2019 | 85.51 Million AUD | 462.9% |
| 2018 | 15.19 Million AUD | 5.9% |
| 2017 | 14.34 Million AUD | 16.19% |
| 2016 | 12.34 Million AUD | -17.92% |
| 2015 | 15.04 Million AUD | 6838.0% |
| 2014 | 216.8 Thousand AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 27.39 Million AUD | -39.18% |
| 2024 Q4 | 27.39 Million AUD | 0.0% |
| 2024 Q1 | 45.03 Million AUD | -32.85% |
| 2024 Q2 | 45.03 Million AUD | 0.0% |
| 2024 FY | 27.39 Million AUD | -59.16% |
| 2023 Q3 | 67.06 Million AUD | -24.22% |
| 2023 Q4 | 67.06 Million AUD | 0.0% |
| 2023 Q1 | 88.5 Million AUD | 74.6% |
| 2023 Q2 | 88.5 Million AUD | 0.0% |
| 2023 FY | 67.06 Million AUD | 32.32% |
| 2022 Q1 | 67.49 Million AUD | -20.4% |
| 2022 FY | 50.68 Million AUD | -40.22% |
| 2022 Q4 | 50.68 Million AUD | 0.0% |
| 2022 Q3 | 50.68 Million AUD | -24.9% |
| 2022 Q2 | 67.49 Million AUD | 0.0% |
| 2021 FY | 84.79 Million AUD | -24.54% |
| 2021 Q1 | 95.28 Million AUD | -15.2% |
| 2021 Q2 | 95.28 Million AUD | 0.0% |
| 2021 Q3 | 84.79 Million AUD | -11.01% |
| 2021 Q4 | 84.79 Million AUD | 0.0% |
| 2020 Q4 | 112.36 Million AUD | 0.0% |
| 2020 FY | 112.36 Million AUD | 31.4% |
| 2020 Q1 | 81.24 Million AUD | -4.98% |
| 2020 Q2 | 81.24 Million AUD | 0.0% |
| 2020 Q3 | 112.36 Million AUD | 38.3% |
| 2019 Q2 | 20.51 Million AUD | 0.0% |
| 2019 Q3 | 85.51 Million AUD | 316.91% |
| 2019 Q4 | 85.51 Million AUD | 0.0% |
| 2019 FY | 85.51 Million AUD | 462.9% |
| 2019 Q1 | 20.51 Million AUD | 35.02% |
| 2018 Q1 | 16.27 Million AUD | 13.48% |
| 2018 Q2 | 16.27 Million AUD | 0.0% |
| 2018 Q3 | 15.19 Million AUD | -6.68% |
| 2018 FY | 15.19 Million AUD | 5.9% |
| 2018 Q4 | 15.19 Million AUD | 0.0% |
| 2017 Q1 | 16.33 Million AUD | 32.33% |
| 2017 FY | 14.34 Million AUD | 16.19% |
| 2017 Q4 | 14.34 Million AUD | 0.0% |
| 2017 Q3 | 14.34 Million AUD | -12.2% |
| 2017 Q2 | 16.33 Million AUD | 0.0% |
| 2016 Q1 | 13.09 Million AUD | 996.51% |
| 2016 Q3 | 12.34 Million AUD | -5.73% |
| 2016 Q4 | 12.34 Million AUD | 0.0% |
| 2016 Q2 | 13.09 Million AUD | 0.0% |
| 2016 FY | 12.34 Million AUD | -17.92% |
| 2015 FY | 15.04 Million AUD | 6838.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | 1.19 Million AUD | 0.0% |
| 2014 FY | 216.8 Thousand AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ContraFect Corporation | 20.67 Million USD | -32.455% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 184.00 USD | -14886007.609% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -897.345% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -5388.637% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 29.491% |
| Kadimastem Ltd | 2.3 Million USD | -1088.78% |
| Zenith Capital Corp. | 7410.00 USD | -369541.538% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -19057.904% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 8.744% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -35772.958% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -7066.951% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 78.965% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -37750.395% |
| Qrons Inc. | 420.00 USD | -6521432.857% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -120133.695% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -8411.475% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -2814.841% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -6244.58% |
| Affymax, Inc. | 7.44 Million USD | -268.003% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 93.863% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1298.764% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -560.644% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -1185633.247% |
| Biomind Labs Inc. | 73.81 Thousand USD | -37004.862% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 48.027% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -10383.295% |
| CytoDyn Inc. | 11.13 Million USD | -145.963% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -159.527% |
| IMV Inc. | 31.33 Million USD | 12.585% |
| Genus plc | 1.02 Billion USD | 97.338% |
| Halberd Corporation | 10.13 Thousand USD | -270262.63% |
| Helix BioMedix, Inc. | 3.02 Million USD | -805.443% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -279.381% |
| LadRx Corporation | 2.3 Million USD | -1086.821% |
| Marizyme, Inc. | 22.01 Million USD | -24.417% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -153090.369% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 22.14% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -6916.604% |
| Q BioMed Inc. | 3.51 Million USD | -679.13% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -7645.792% |
| Enzolytics Inc. | 361.7 Million USD | 92.427% |
| CSL Limited | 38.02 Billion USD | 99.928% |
| Skye Bioscience, Inc. | 11.94 Million USD | -129.393% |
| SQZ Biotechnologies Company | 107.18 Million USD | 74.446% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -726.753% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1916.445% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -10379.805% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -4182.058% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 42.58% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -4268.491% |
| NovAccess Global Inc. | 62.24 Thousand USD | -43902.117% |
| HST Global, Inc. | 1526.00 USD | -1794817.3% |
| SYBLEU INC | 330.46 Thousand USD | -8188.378% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 78.686% |
| Alpha Cognition Inc. | 2.45 Million USD | -1016.988% |
| AVAX Technologies, Inc. | 7.37 Million USD | -271.287% |
| Mesoblast Limited | 667.9 Million USD | 95.899% |
| MultiCell Technologies, Inc. | 126.22 USD | -21700453.003% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1812.697% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -3884.145% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -3454.227% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 94.082% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -952.185% |
| GB Sciences, Inc. | 103.44 Thousand USD | -26379.03% |
| argenx SE | 4.54 Billion USD | 99.397% |
| Resverlogix Corp. | 8.11 Million USD | -237.529% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1358.583% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 1.981% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1790.504% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -206.067% |
| ONE Bio Corp. | 70.08 Million USD | 60.919% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.191% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -2851.68% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -2672.404% |
| Agentix Corp. | 261.39 Thousand USD | -10378.683% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -88.117% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -47874.285% |
| Cell Source, Inc. | 195.17 Thousand USD | -13934.072% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -5599.727% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -7645.792% |
| Itoco Inc. | 1.4 Million USD | -1856.359% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -28534.013% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -25740.036% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -7005.707% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -4860.957% |
| Rebus Holdings, Inc. | 5000.00 USD | -547708.76% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -6590.026% |
| Mobile Lads Corp. | 52.00 USD | -52673819.231% |
| International Stem Cell Corporation | 5.39 Million USD | -408.171% |
| Bioxytran, Inc. | 137.63 Thousand USD | -19800.346% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -82.581% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -65.212% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -34571.441% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -3067.707% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -264.38% |
| Neutra Corp. | 2851.00 USD | -960630.901% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 15.477% |
| PureTech Health plc | 693.97 Million USD | 96.053% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -239.365% |
| IXICO plc | 15.84 Million USD | -72.877% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -230.723% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 73.491% |
| CSL Limited | 38.02 Billion USD | 99.928% |
| Cellectis S.A. | 333.99 Million USD | 91.799% |